Literature DB >> 23928981

Distant metastatic lesions in patients with differentiated thyroid carcinoma. Clinical implications of radioiodine and FDG uptake.

C M Hong1, B-C Ahn, S Y Jeong, S-W Lee, J Lee.   

Abstract

AIM: Many investigators have reported an inverse relationship between iodine and glucose utilization of differentiated thyroid carcinoma (DTC) according to its degree of differentiation; however, not every DTC is compatible with this phenomenon. This study was conducted to evaluate the clinical implication of iodine and glucose uptake at distant metastatic lesions in DTC patients. PATIENTS,
METHODS: 64 DTC patients (women 47; mean age 49.9 ± 16.4 years) with distant metastasis who underwent post (131)I treatment whole-body scan (RxWBS) and FDG PET/CT were included in the study. Radioiodine (RAI) and FDG uptake of metastatic lesions were evaluated. TSH stimulated serum thyroglobulin (s-Tg) were obtained.
RESULTS: 53 of 64 patients (82.8%) were RAI(+) group, and 37 patients (57.8%) were FDG(+) group. Patients in the RAI(-) group showed a higher rate of FDG uptake than RAI(+) group (100.0% vs. 49.1%, p = 0.002). Patients in the FDG(-) group showed a higher rate of RAI uptake than FDG(+) group (100.0% vs. 70.3%, p = 0.002). Patients with s-Tg < 100 ng/ml were frequently observed in the FDG(-)/RAI(+) group and the FDG(+)/RAI(-) group (p = 0.023). And patients with s-Tg ≥ 500 ng/ml were more frequently observed in the FDG(+)/RAI(+) group, compared with the FDG(+)/RAI(-) group (p = 0.036). Reduced disease-specific survival (DSS) was observed in patients with RAI(-) (p = 0.003), FDG(+) (p = 0.006), SUVmax > 3.6 (p<0.001), and s-Tg > 75.8 ng/ml (p = 0.009). In multivariate analysis, only a SUVmax > 3.6 was significantly predictive of DSS (p = 0.006).
CONCLUSION: An inverse relationship between RAI and FDG uptake, flip-flop phenomenon, was observed in patients with metastatic lesions of DTC. Reduced disease-specific survival was observed in patients with FDG(+), RAI(-) in metastatic lesions, or high s-Tg value.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23928981     DOI: 10.3413/Nukmed-0541-12-11

Source DB:  PubMed          Journal:  Nuklearmedizin        ISSN: 0029-5566            Impact factor:   1.379


  17 in total

1.  Difference of clinical and radiological characteristics according to radioiodine avidity in pulmonary metastases of differentiated thyroid cancer.

Authors:  Do-Hoon Kim; Ji-Hoon Jung; Seung Hyun Son; Choon-Young Kim; Chae Moon Hong; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2013-10-15

Review 2.  Novel Approaches to Thyroid Cancer Treatment and Response Assessment.

Authors:  Ravinder K Grewal; Alan Ho; Heiko Schöder
Journal:  Semin Nucl Med       Date:  2016-03       Impact factor: 4.446

Review 3.  KSNM60 in Nuclear Endocrinology: from the Beginning to the Future.

Authors:  Chae Moon Hong; Young Jin Jeong; Hae Won Kim; Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2022-01-24

4.  Circ 003390/Eukaryotic translation initiation factor 4A3 promoted cell migration and proliferation in endometrial cancer via vascular endothelial growth factor signaling by miR-195-5p.

Authors:  Jing Ma; Xiwa Zhao; Li Shi
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

5.  The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients.

Authors:  Martin Barrio; Johannes Czernin; Michael W Yeh; Miguel F Palma Diaz; Pawan Gupta; Martin Allen-Auerbach; Christiaan Schiepers; Ken Herrmann
Journal:  Nucl Med Commun       Date:  2016-12       Impact factor: 1.690

6.  Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas.

Authors:  Johanna Wassermann; Marie-Odile Bernier; Jean-Philippe Spano; Charlotte Lepoutre-Lussey; Camille Buffet; Jean-Marc Simon; Fabrice Ménégaux; Frédérique Tissier; Monique Leban; Laurence Leenhardt
Journal:  Oncologist       Date:  2015-12-16

Review 7.  Factors Associated with Dose Determination of Radioactive Iodine Therapy for Differentiated Thyroid Cancer.

Authors:  Chae Moon Hong; Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2018-05-02

8.  The Predictive Values of Lesion Size, F-18 FDG Avidity and I-131 Avidity for the Clinical Outcome of I-131 Treatment in Patients with Metastatic Differentiated Thyroid Carcinoma Only in the Lung.

Authors:  Joon Ho Choi; Byung Hyun Byun; Ilhan Lim; Hansol Moon; Jihyun Park; Kyoung Jin Chang; Byung Il Kim; Chang Woon Choi; Sang Moo Lim
Journal:  Nucl Med Mol Imaging       Date:  2017-11-07

9.  Investigating 18F-FDG PET/CT Parameters as Prognostic Markers for Differentiated Thyroid Cancer: A Systematic Review.

Authors:  Hongxi Wang; Hongyuan Dai; Qianrui Li; Guohua Shen; Lei Shi; Rong Tian
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

Review 10.  Personalized Medicine Based on Theranostic Radioiodine Molecular Imaging for Differentiated Thyroid Cancer.

Authors:  Byeong-Cheol Ahn
Journal:  Biomed Res Int       Date:  2016-04-28       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.